U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...

Ahead of a Senate hearing centered on high prices for Novo Nordisk’s in-demand semaglutide ... of the drugs to enter the market. Sen. Elizabeth Warren, D-Massachusetts, Rep.

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

US Senators Elizabeth Warren (D-Mass), Jeanne Shaheen (D-NH), and Reverend Raphael Warnock (D-Ga) have sent a letter (PDF) to Novo Nordisk to request more information on the decision to ...

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide ...

Elizabeth Warren is continuing the fight to persuade ... and Human Services Secretary Xavier Becerra to waive the patents Novo Nordisk uses to protect two popular GLP-1 agonist drugs, Ozempic ...